1. Article title:

Cytochrome 4Z1 expression is associated with unfavorable survival in triple-negative breast cancers

2. Article author or authors

Yousef M Al-Saraireh, Fatemah OFO Alshammari, Ahmed MM Youssef, Fatima Al-Tarawneh, Sameeh Al-Sarayreh, Ghadeer H Almuhaisen, Anas O Satari, Jehad Al-Shuneigat, Hamzeh Mohammad Alrawashdeh
3. Name of journal and date of publication

Breast Cancer: Targets and Therapy (2021/10/5)
4. Article abstract

Purpose

Triple-negative breast cancer (TNBC) is characterized by high mortality rate, and its clinical management is difficult and complex. Therefore, there is a need for extensive efforts aimed at accelerating the discovery of novel therapies for TNBC. CYP4Z1 has been implicated in the development of breast cancer. The current study aimed at characterizing the expression of CYP4Z1 on TNBC.

Materials and Methods

Using immunohistochemistry, CYP4Z1 expression was evaluated on 122 TNBC samples, four samples of breast cancers expressing ER, PR, and HER-2, and four samples of normal breast tissues. The association between the enzyme and various histopathological features and survival of patients were determined.

Results

CYP4Z1 was strongly expressed in 83.3% of various histopathological subtypes of TNBC, when compared to negative expression in normal breast tissues. Interestingly, there were marked variations in CYP4Z1 expression with respect to histopathology subtype, histological grade, histological stage and tumor diameter. There was a high incidence of CYP4Z1 expression in patients with advanced grades, late stages and larger tumor sizes. Importantly, CYP4Z1 expression was correlated with the survival of TNBC patients, but it was an independent determinant of the poor prognosis of TNBC (p< 0.05).

Conclusion

CYP4ZI may be a potential biomarker or target for evolving new CYP4Z1-targeted treatments.